Septerna (NASDAQ:SEPN) Trading Up 6.7% – Here’s Why

Septerna, Inc. (NASDAQ:SEPN) traded up 6.7% during trading on Monday . The company traded as high as $26.50 and last traded at $27.1450. 11,999 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 555,518 shares. The stock had previously closed at $25.44.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SEPN. Wells Fargo & Company raised shares of Septerna from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $18.00 to $28.00 in a report on Friday, November 14th. Wall Street Zen upgraded Septerna from a “sell” rating to a “buy” rating in a research report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. HC Wainwright lifted their target price on Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Truist Financial started coverage on Septerna in a report on Monday. They issued a “buy” rating and a $34.00 target price on the stock. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.25.

Septerna Stock Up 5.8%

The stock has a market capitalization of $1.20 billion, a PE ratio of -17.89 and a beta of 3.76. The firm’s fifty day moving average is $23.23 and its 200-day moving average is $16.35.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The business had revenue of $21.50 million during the quarter, compared to analysts’ expectations of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. On average, analysts expect that Septerna, Inc. will post -7.11 EPS for the current year.

Insider Activity at Septerna

In other news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the transaction, the senior vice president directly owned 92,911 shares of the company’s stock, valued at $1,677,972.66. This represents a 3.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 4.30% of the company’s stock.

Institutional Trading of Septerna

A number of institutional investors have recently added to or reduced their stakes in SEPN. Deutsche Bank AG increased its holdings in Septerna by 53.3% in the first quarter. Deutsche Bank AG now owns 15,968 shares of the company’s stock valued at $92,000 after buying an additional 5,549 shares in the last quarter. Swiss National Bank acquired a new stake in shares of Septerna in the 1st quarter worth approximately $174,000. Nuveen LLC purchased a new position in Septerna in the 1st quarter valued at approximately $139,000. Stoneridge Investment Partners LLC acquired a new position in Septerna during the first quarter worth $107,000. Finally, Stonepine Capital Management LLC acquired a new position in Septerna during the first quarter worth $394,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.